Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01858545 · ClinicalTrials.gov registry record · NA
A Comparative Efficacy Study: Treatment for Non-healing Diabetic Foot Ulcers
A NA study, sponsored by Integra LifeSciences Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT01858545 is a NA study that was terminated before completion, run by Integra LifeSciences Corporation. The registered enrollment target is 56 participants.
The verdict
NCT01858545, a NA study, was terminated before completion, sponsored by Integra LifeSciences Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the effectiveness of MatriStem devices compared to cellular dermal replacement tissue, for the treatment of non-healing diabetic foot ulcers.
Interventions
- DEVICE MatriStem
- DEVICE Cellular Dermal Replacement Tissue
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01858545
The ClinicalTrials.gov registry entry for NCT01858545 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Integra LifeSciences Corporation, which has 60 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MatriStem is the first listed.
NCT01858545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01858545 about?
NCT01858545 is a clinical study titled "A Comparative Efficacy Study: Treatment for Non-healing Diabetic Foot Ulcers". The primary objective of this study is to assess the effectiveness of MatriStem devices compared to cellular dermal replacement tissue, for the treatment of non-healing diabetic foot ulcers.
What is the current status of trial NCT01858545?
This trial is currently terminated. It is a NA study. The enrollment target is 56 participants. The study started on 2013-05. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01858545?
The interventions under investigation include: MatriStem (DEVICE), Cellular Dermal Replacement Tissue (DEVICE).
Who is sponsoring clinical trial NCT01858545?
This trial is sponsored by Integra LifeSciences Corporation, which has 60 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.